10 High Growth Healthcare Stocks to Invest in Now

3. Argenx SE (NASDAQ:ARGX)

Revenue Growth: 96.06% 

Argenx SE (NASDAQ:ARGX) is a global biotechnology company specializing in developing antibody-based therapies for autoimmune diseases and cancer. At its core, the company creates innovative treatments targeting rare and severe autoimmune conditions, with its flagship product VYVGART (efgartigimod) leading the charge.

Argenx SE (NASDAQ:ARGX) reported strong Q3 2024 results with total operating income of $589 million and product net sales of $573 million, reflecting 20% quarter-over-quarter and 74% year-over-year growth. U.S. net sales were $492 million, and the company achieved a gross margin of 90%. Operating profit was $14 million, with a cash balance of $3.4 billion. The growth was mainly driven by the success of VYVGART in gMG and the strong launch of VYVGART Hytrulo in CIDP.

The company’s CIDP launch exceeded expectations, treating over 300 patients by Q3’s end. Argenx SE (NASDAQ:ARGX) is targeting markets for gMG, and CIDP, and expanding globally, with VYVGART already available to 80% of the gMG population in the EU and early success in Japan’s ITP launch. The corporation is also pursuing additional indications, including myositis.

Street analysts hold a consensus Strong Buy rating on the stock. The average 12-month price target is $665.45 from 23 Wall Street analysts. The target range is between $560.00 and $770.00, representing a 9.82% upside from the last price of $605.92.